Tradestie Institutional Equity Comparison Engine

WGS vs CDNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDNA Overall Edge

CDNA Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CareDx, Inc. (CDNA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while WGS counters with relative strength in Valuation. Fundamentally, WGS trades at 40.6x Forward P/E with -13.7% operating margin (+5.4% YoY revenue) versus CDNA at 47.1x Forward P/E and 1.6% operating margin (+39.3% YoY). In options structure, WGS sits in BREAKDOWN (21st %ile IV; Dealer Gamma Walls on Pro) against CDNA sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner WGS
WGS 40.6x vs CDNA 47.1x Fwd P/E
Growth & Margin Winner CDNA
Op Margin -13.7% vs 1.6% ยท YoY +5.4% vs +39.3%
Momentum & Technical Winner CDNA
1Y -60.9% vs +364.5% ยท 52W Pos 14% vs 77%
Options & Structure Winner CDNA
BREAKDOWN (21st %ile IV) vs CONSOLIDATION (18th %ile IV)
WGS NASDAQ
GeneDx Holdings Corp. Class A Common Stock
Services-Health Services
$51.02
-2.58% 1D
Market Cap $1.6B
1M Return -19.79%
1Y Return -60.86%
Forward P/E 40.6x
Unified AI Score
49.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 70.0 Mom 60.0
CDNA NASDAQ
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap $4.1B
1M Return +15.19%
1Y Return +364.52%
Forward P/E 47.1x
Unified AI Score
24.5 / 100 STRONG SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 25.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: WGS -60.86% CDNA +364.52% Spread: +425.38 pp (CDNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period WGS Revenue CDNA Revenue WGS Op. Margin CDNA Op. Margin Margin Edge
FY2018 N/A $80M N/A -20.3% CDNA
FY2019 $200M $130M -15.5% -19.3% WGS
FY2020 $180M $190M -134.9% -11.7% CDNA
FY2021 $210M $300M -210.3% -10.0% CDNA
FY2022 $230M $320M -284.5% -24.0% CDNA
FY2023 $200M $280M -89.2% -72.5% CDNA
FY2024 $310M $330M -7.6% 12.2% CDNA
FY2025 $430M $380M -3.1% -8.1% WGS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: WGS (2) vs CDNA (8)
Institutional Metric WGS CDNA Criterion Row Winner
Market Capitalization Scale $1.6B $4.1B Larger Scale CDNA
Trailing P/E Ratio Valuation 38.8x 32.9x Lower Multiple CDNA
Forward P/E Ratio Valuation 40.6x 47.1x Lower Multiple WGS
Revenue Growth (YoY) Growth +5.4% +39.3% Higher Growth CDNA
Operating Margin (TTM) Profitability -13.7% 1.6% Higher Margin CDNA
Net Profit Margin Profitability -24.1% 25.9% Higher Margin CDNA
Return on Equity (ROE) Capital Efficiency -41.4% 33.0% Higher ROE CDNA
52-Week Range Position Momentum 14% ($32โ€“$171) 77% ($15โ€“$91) Stronger Trend CDNA
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 111% Vol 1.21ฮฒ ยท 98% Vol Lower Realized Risk CDNA
Unified Institutional Score Composite Signal 49.5 / 100 (HOLD) 24.5 / 100 (STRONG SELL) Higher Composite WGS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full WGS vs CDNA Buy Guide
WGS BREAKDOWN
96d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live WGS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
30d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live CDNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither WGS nor CDNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.